Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02160249
Other study ID # 7035
Secondary ID 100142/Z/12/Z
Status Completed
Phase N/A
First received June 3, 2014
Last updated May 9, 2017
Start date September 2015
Est. completion date May 8, 2017

Study information

Verified date May 2017
Source London School of Hygiene and Tropical Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether community-based rehabilitation plus facility-based care is superior to facility-based care alone in reducing disability related to schizophrenia in rural Ethiopia.


Description:

This is a cluster randomised trial set in rural Ethiopia with kebeles (villages) as the unit of randomisation. 54 kebeles will be included. 27 will be randomly allocated to the intervention arm (Facility based care (FBC) + Community-based Rehabilitation (CBR)) and 27 randomly allocated to the control arm (FBC alone).

The aim is to determine whether CBR + FBC is superior to FBC alone in reducing disability related to schizophrenia, measured by the WHO Disability Assessment Schedule version 2.0 (WHODAS 2.0) at 6 and 12 months.


Recruitment information / eligibility

Status Completed
Enrollment 166
Est. completion date May 8, 2017
Est. primary completion date March 26, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age =18 years

- Diagnosis of schizophrenia spectrum disorder (schizophrenia, schizoaffective disorder or schizophreniform disorder) using (DSM-IV) criteria

- Evidence of severe, enduring or disabling illness

- Resident in kebele for >6 months and no immediate plans to leave the kebele

- Has a primary caregiver who is willing to participate in the study

Exclusion Criteria:

- No specific criteria

Study Design


Intervention

Behavioral:
Community-based rehabilitation

Other:
Facility based care


Locations

Country Name City State
Ethiopia Department of Psychiatry, College of Health Sciences, Addis Ababa University Addis Ababa

Sponsors (2)

Lead Sponsor Collaborator
London School of Hygiene and Tropical Medicine Addis Ababa University

Country where clinical trial is conducted

Ethiopia, 

Outcome

Type Measure Description Time frame Safety issue
Other Discrimination (DISC-12) Potential mediator 6 and 12 months
Other Health service use and costs Potential mediator 6 and 12 months
Other Depression (PHQ-9+1) Potential confounder 6 and 12 months
Other Access/ adherence to CBR and reasons for non-adherence Potential mediator 6 and 12 months
Other Social support (OSLO-3) Potential mediator 6 and 12 months
Other Stigma and discrimination (WHO Family Interview Schedule Stigma section) 6 and 12 months
Primary Disability (36-item WHODAS (World Health Organisation Disability Assessment Schedule) 2.0) 12 months
Secondary Symptom severity (Brief Psychiatric Rating Scale- Expanded version (BPRS-E)) 6 and 12 months
Secondary Clinical Global Impression (CGI) 6 and 12 months
Secondary Relapse (Longitudinal Interval Follow up Evaluation: DSM-IV version (LIFE)) 6 and 12 months
Secondary Disability (36-item WHODAS 2.0) 6 months
Secondary Functioning (indigenous functioning scale) Scale is currently under development. It is being designed and validated to measure functioning in people with severe mental illness in rural Ethiopia. 6 and 12 months
Secondary Economic activity of patient (employment, income and household work) Section includes current occupation (categories), employment status (categories), typical income (specific amount). Section also includes questions adapted from the WHO-DAS 12 and 36 relating to problems doing usual work task both generally and as a result of their mental illness (likert scale) 6 and 12 months
Secondary Medication adherence (4 item Morisky Medication Adherence Scale) 6 and 12 months
Secondary Engagement with facility based care Potential mediator 6 and 12 months
Secondary Proportion with human rights problems (chaining or restraint)- self-reported The outcome is the proportion chained, restrained or confined within last one month. Additional data on who perpetrated the chaining i.e. traditional healer/ family member will be collected. 6 and 12 months
Secondary Nutritional status (BMI) 6 and 12 months
Secondary Serious adverse events 6 and 12 months
Secondary Economic activity of caregiver Section includes current occupation (categories), employment status (categories), typical income (specific amount). Section also includes questions adapted from the WHO-DAS 12 and 36 relating to problems doing usual work tasks (likert scale). 6 and 12 months
Secondary Caregiver burden (WHO Family Interview Schedule Impact section) 6 and 12 months
Secondary Caregiver depression (PHQ9 +1) 6 and 12 months
Secondary Patient medication adherence 6 and 12 months
Secondary Proportion with human rights problems (chaining or restraint)- Caregiver-reported Caregiver to report presence of human rights problems relating to patient. The outcome is the proportion chained, restrained or confined within last one month. Additional data on who perpetrated the chaining i.e. traditional healer/ family member will be collected. 6 and 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A